Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bibby

Showing results (121-130 of 204) with videos related to

Pageof 21
Sort By:
Journal of Chromatography. B, Biomedical Sciences and Applications|July 20, 2000
High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxideD J Swaine, P M Loadman, M C Bibby, et al.
Molecular Medicine Reports|April 8, 2011
Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10Ekatherine M Prokopiou, Patricia A Cooper, George R Pettit, et al.
International Journal of Oncology|December 5, 2003
The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatmentD Alwyn Dart, Steven M Picksley, Patricia A Cooper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1P M Loadman, M C Bibby, J A Double, et al.
International Journal of Oncology|July 6, 2007
Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour modelsSteven D Shnyder, Patricia A Cooper, Nicola J Millington, et al.
British Journal of Cancer|March 1, 1992
In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicityR M Phillips, P B Hulbert, M C Bibby, et al.
British Journal of Cancer|April 3, 1999
Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in miceM C Bibby, M J Thompson, J A Rafferty, et al.
Archiv Der Pharmazie|November 1, 1996
Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 1: 6-Methyl derivativesR A Aitken, M C Bibby, J A Double, et al.
Anti-Cancer Drug Design|March 1, 1996
Pharmacokinetics and anti-tumour activity of B.4152, a reactive molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, and its uracil analogueP M Loadman, A M Matthew, J E McCormick, et al.
Pharmaceutical Research|August 16, 2002
A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheresAnne Aubert-Pouëssel, David C Bibby, Marie-claire Venier-Julienne, et al.
Pageof 21

Showing results (121-130 of 204) with videos related to

Sort By:
Pageof 21
Journal of Chromatography. B, Biomedical Sciences and Applications|July 20, 2000
High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxideD J Swaine, P M Loadman, M C Bibby, et al.
Molecular Medicine Reports|April 8, 2011
Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10Ekatherine M Prokopiou, Patricia A Cooper, George R Pettit, et al.
International Journal of Oncology|December 5, 2003
The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatmentD Alwyn Dart, Steven M Picksley, Patricia A Cooper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1P M Loadman, M C Bibby, J A Double, et al.
International Journal of Oncology|July 6, 2007
Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour modelsSteven D Shnyder, Patricia A Cooper, Nicola J Millington, et al.
British Journal of Cancer|March 1, 1992
In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicityR M Phillips, P B Hulbert, M C Bibby, et al.
British Journal of Cancer|April 3, 1999
Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in miceM C Bibby, M J Thompson, J A Rafferty, et al.
Archiv Der Pharmazie|November 1, 1996
Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 1: 6-Methyl derivativesR A Aitken, M C Bibby, J A Double, et al.
Anti-Cancer Drug Design|March 1, 1996
Pharmacokinetics and anti-tumour activity of B.4152, a reactive molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, and its uracil analogueP M Loadman, A M Matthew, J E McCormick, et al.
Pharmaceutical Research|August 16, 2002
A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheresAnne Aubert-Pouëssel, David C Bibby, Marie-claire Venier-Julienne, et al.
Pageof 21